Search Result

Results for "

tachycardia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adrenergic Receptor (16) Angiotensin-converting Enzyme (ACE) (1) ATP Synthase (1) Calcium Channel (13) Dopamine Receptor (3) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (1) Isotope-Labeled Compounds (3) Myosin (1) Parasite (1) Potassium Channel (12) Reactive Oxygen Species (ROS) (3) Reference Standards (5) Sodium Channel (6)
By Research Areas:	Cancer (3) Cardiovascular Disease (35) Endocrinology (3) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W010950

Flecainide 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-119850

Aladorian ARM036; S44121	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-B1470

Azaperone R-1929	Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent .

HY-149662

TMDJ-035	Calcium Channel ATP Synthase Myosin	Cardiovascular Disease
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC₅₀ of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca ²⁺ transients. TMDJ-035 decreases ATP content and intracellular Ca ²⁺ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .

HY-17611

Etripamil MSP-2017; (-)-MSP-2017	Calcium Channel	Cardiovascular Disease Neurological Disease
Etripamil (MSP-2017) is a short-acting, L-type calcium-channel antagonist. Etripamil inhibits calcium influx through slow calcium channels, thereby slowing AV node conduction and prolonging the AV node refractory period. Etripamil increases heart rate and decreases systolic blood pressure. Etripamil can be used in the study of paroxysmal supraventricular tachycardia (PSVT) .

HY-100607A

Landiolol hydrochloride ONO1101 hydrochloride	Adrenergic Receptor Calcium Channel Potassium Channel Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Endocrinology
Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β₁ adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β₁ receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .

HY-W010950A

Flecainide hydrochloride 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-14304A

Zinterol hydrochloride 1 Publications Verification MJ 9184 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist . Zinterol hydrochloride increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM . Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits .

HY-101172

RS 23597-190 EP-A-501322	5-HT Receptor	Cardiovascular Disease
RS 23597-190 (EP-A-501322) is a high affinity and selective 5-HT4 receptor antagonist. RS 23597-190 inhibits Serotonin (HY-B1473A)-induced tachycardia. RS 23597-190 significantly inhibits superoxide production in high glucose .

HY-B0006C

(R)-Carvedilol (R)-BM 14190	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Cancer
(R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

HY-N1924

Crassicauline A Crassicaulin A	Parasite	Cardiovascular Disease Infection
Crassicauline A (Crassicaulin A) is a diester-type diterpenoid alkaloid. Crassicauline A exhibits feeding deterrent activity against adult Tribolium castaneum, with a EC₅₀ of 1134.5 ppm. Crassicauline A induces arrhythmia at a dose of 0.10 mg/kg .

HY-101222

SB-203186 hydrochloride	5-HT Receptor	Cardiovascular Disease Neurological Disease
SB-203186 hydrochloride is a potent, selective and competitive 5-HT₄ antagonist. SB-203186 hydrochloride antagonizes the 5-HT₄ receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pK_B values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively .

HY-167902

YM-31636 free base	5-HT Receptor	Metabolic Disease
YM-31636 free base is an orally active, potent and selective 5-HT₃ receptor agonist with a K_i value of 0.2 nM. YM-31636 free base induces contraction of isolated guinea pig distal colon. YM-31636 free base induces tachycardia with the relative intrinsic activity of approximately 0.23 in isolated guinea pig right atrium. YM-31636 free base is promising for research of constipation .

HY-16094

Bethanidine sulfate BW 467C60	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Bethanidine sulfate (BW 467C60) is an orally active antihypertensive agent and adrenergic neuron blocker. Bethanidine sulfate exerts its antihypertensive effect by inhibiting the release of norepinephrine from sympathetic nerve terminals. Bethanidine sulfate exhibits anti-ventricular arrhythmic activity. Bethanidine sulfate can be used in research related to hypertension, ventricular tachycardia, and ventricular fibrillation .

HY-W010950S

Flecainide-d3	Potassium Channel Sodium Channel Isotope-Labeled Compounds	Cardiovascular Disease
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-135439

SB-203186	5-HT Receptor	Neurological Disease
SB-203186 is a highly selective 5-HT₄ receptor antagonist. SB-203186 exhibits a potent competitive antagonistic effect, with its pK_B value being 8.3 in the isolated right atrium model of piglets. SB-203186 can dose-dependently shift the 5-HT-induced tachycardia curve to the right, and does not inhibit the maximum response. SB-203186 is an efficient 5-HT₄ antagonist in pig and human atria, but has no significant inhibitory effect in rat atria. SB-203186 can be used for the study of diseases such as arrhythmias and abnormal myocardial contraction .

HY-108582

Y-27152	Potassium Channel	Cardiovascular Disease
Y-27152, a proagent of the K_ATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state .

HY-14304

Zinterol MJ 9184	Adrenergic Receptor	Cardiovascular Disease
Zinterol (MJ 9184) is a potent and selective β2-adrenoceptor agonist . Zinterol increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM .

HY-113322

3-Hydroxyquinine 3-Hydroxyquinidine	Drug Metabolite	Cardiovascular Disease
3-Hydroxyquinine is a metabolite of Quinidine (HY-B1751). 3-Hydroxyquinine prevents ventricular fibrillation and ventricular tachycardia after coronary reperfusion in an isolated rat heart reperfusion arrhythmia model in a concentration-dependent manner. 3-Hydroxyquinine can be used in the study of cardiac arrhythmias .

HY-B1470S

Azaperone-d4 R-1929-d₄	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-W010950AR

Flecainide hydrochloride (Standard)	Reference Standards Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-W010950R

Flecainide (Standard)	Reference Standards Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-113695

BW A575C	Angiotensin-converting Enzyme (ACE) Adrenergic Receptor	Cardiovascular Disease
BW A575C is a dual inhibitor against angiotensin converting enzyme (ACE) and β-adrenoceptor. BW A575C produces a competitive blockade of Isoprenaline (HY-108353)-induced tachycardia in a guinea-pig right atrial. BW A575C also inhibits Angiotensin I (HY-P1032)-induced pressor responses in rats. BW A575C is promising for research of hypertensive diseases .

HY-124883

R-(–)-Flecainide	Drug Isomer	Cardiovascular Disease
R-(–)-Flecainide is an orally active antiarrhythmic agent, which inhibits ventricular ectopic activity .

HY-111018

FPL 62129	Calcium Channel	Cardiovascular Disease
FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator .

HY-116759

VU0405601	Potassium Channel	Cardiovascular Disease
VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia .

HY-119850A

Aladorian sodium ARM036 sodium; S44121 sodium	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca ²⁺ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-17611A1

Etripamil hydrochloride MSP-2017 hydrochloride; (-)-MSP-2017 hydrochloride	Calcium Channel	Neurological Disease
Etripamil (MSP-2017) hydrochloride is a short-acting, L-type calcium channel antagonist that can be used in the study of paroxysmal supraventricular tachycardia (PSVT). Etripamil hydrochloride inhibits calcium influx through slow calcium channels, thereby slowing atrioventricular node conduction and prolonging the atrioventricular node refractory period.

HY-105515

TJN 220	Others	Cardiovascular Disease
TJN 220 is a synthetic derivative of orally active tetrandrine (HY-13764). TJN 220 has a long-lasting and stable antihypertensive effect in various hypertension models. TJN 220 is suitable for controlling nighttime hypertension and does not cause reflex tachycardia. TJN 220 can be used for research on hypertension .

HY-135488

A 131701	Adrenergic Receptor	Cardiovascular Disease
A 131701 is a selective α1a- (K_i: 0.22 nM for human α1a) and α1d-adrenoceptor antagonist. A 131701 antagonizes epinephrine-induced increases in intraurethral pressure (IUP). A 131701 causes transient decreases in mean arterial blood pressure (MABP) and transient tachycardia. A 131701 can be used in the research of spontaneous hypertension .

HY-116500A

AH-1058	Calcium Channel	Cardiovascular Disease
AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes.

HY-116790B

(±)-Penbutolol (Rac)-Penbutolol; (±)-Isopenbutolol	Adrenergic Receptor	Cardiovascular Disease
(±)-Penbutolol ((Rac)-Penbutolol) is the racemic mixture of Penbutolol. (±)-Penbutolol is an orally active β-adrenergic receptor antagonist. (±)-Penbutolol antagonizes exercise-induced tachycardia, reduces the increase in peak expiratory flow rate (PEFR) caused by exercise, and decreases resting plasma renin activity (PRA). (±)-Penbutolol reaches peak plasma concentration 1 hour after oral administration, with a half-life of 4.5 hours, and is converted into an active metabolite in the body. (±)-Penbutolol can be used in cardiovascular-related disease research .

HY-B0006CS

(R)-Carvedilol-d4 (R)-BM 14190-d₄	Isotope-Labeled Compounds Adrenergic Receptor Calcium Channel	Cardiovascular Disease Cancer
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

HY-B1470R

Azaperone (Standard) R-1929 (Standard)	Reference Standards Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone (R-1929) (Standard) is the analytical standard of Azaperone (HY-B1470). This product is intended for research and analytical applications. Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-100607

Landiolol ONO1101	Adrenergic Receptor Calcium Channel Potassium Channel Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Endocrinology
Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β₁ adrenergic receptors. Landiolol specifically blocks cardiac β₁ receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .

HY-100607AR

Landiolol hydrochloride (Standard) ONO1101 hydrochloride (Standard)	Reference Standards Adrenergic Receptor Calcium Channel Potassium Channel Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Endocrinology
Landiolol (ONO1101) hydrochloride (Standard) is the analytical standard of Landiolol hydrochloride (HY-100607A). This product is intended for research and analytical applications. Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β₁ adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β₁ receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .

HY-101431

Xibenolol hydrochloride D32 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Xibenolol hydrochloride (D32 hydrochloride) is an orally active beta-adrenoceptor blocking agent. Xibenolol hydrochloride can be used in the research of tachycardia and hypotension .

HY-119200

LY-195448 hydrochloride	Endogenous Metabolite	Cancer
LY-195448 hydrochloride is a phenethanolamine that exhibits anti-tumour activity across various murine tumour models. LY-195448 hydrochloride acts by blocking cells at metaphase. LY-195448 hydrochloride has demonstrated a lack of "standard" side effects commonly associated with cancer treatments, such as myelosuppression and gastrointestinal toxicity. LY-195448 hydrochloride was evaluated in a phase I trial, where it showed only mild and reversible side effects like hypotension, tachycardia, and tremor.

HY-101172R

RS 23597-190 (Standard) EP-A-501322 (Standard)	5-HT Receptor Reference Standards	Cardiovascular Disease
RS 23597-190 (Standard) is the analytical standard of RS 23597-190 (HY-101172). This product is intended for research and analytical applications. RS 23597-190 (EP-A-501322) is a high affinity and selective 5-HT4 receptor antagonist. RS 23597-190 inhibits Serotonin (HY-B1473A)-induced tachycardia. RS 23597-190 significantly inhibits superoxide production in high glucose .

HY-182635

ICI 147798	Adrenergic Receptor Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease
ICI 147798 is an orally effective β-adrenoceptor antagonist with a pK_B of 9.1 (in guinea pig right atrium) and 8.8 (in guinea pig trachea). ICI 147798 acts as a diuretic and intraocular pressure-lowering agent. ICI 147798 blocks β-adrenoceptors, inhibits isoproterenol-induced tachycardia and vasodepressor responses, exhibits slowly dissociating, insurmountable antagonism against β₁-adrenoceptors, and shows surmountable competitive antagonism against β₂-adrenoceptors. ICI 147798 induces natriuresis and kaliuresis, inhibits sodium transport, and reduces intraocular pressure .

HY-183206

UR 8225	Potassium Channel Calcium Channel	Cardiovascular Disease Inflammation/Immunology
UR 8225 is an orally active ATP-sensitive K ⁺ channel activator with vasodilator, smooth muscle relaxant, antihypertensive, and bronchodilator activities. UR 8225 induces membrane hyperpolarization by increasing outward K ⁺ conductance and reduces Ca ²⁺ influx through voltage-gated L-type Ca ²⁺ channels. UR 8225 reduces total peripheral vascular resistance, shortens cardiac action potential duration, inhibits agonist-induced Ca ²⁺ influx, and stimulates renin release. UR 8225 induces reflex tachycardia but lacks β-adrenergic receptor blocking activity. UR 8225 is widely applicable to research in fields related to hypertension, myocardial ischemia, ventricular fibrillation, and other conditions .

HY-105439A

Clofilium phosphate LY 150378	Drug Derivative	Cardiovascular Disease
Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias .

Cat. No.	Product Name	Target	Research Area

HY-P5494

DPc10	Peptides	Others
DPc10 is a biological active peptide. (This is amino acids 2460 to 2495 fragment of cardiac ryanodine receptor (RyR2). RyR2 controls calcium release from the sarcoplasmic reticulum, which begins muscle contraction. Mutated RyR2 is associated to ventricular tachycardia (VT) and sudden death.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1924

Crassicauline A Crassicaulin A	Alkaloids Structural Classification Other Alkaloids Ranunculaceae Aconitum carmichaeli Debx. Plants Source Classification	Parasite
Crassicauline A (Crassicaulin A) is a diester-type diterpenoid alkaloid. Crassicauline A exhibits feeding deterrent activity against adult Tribolium castaneum, with a EC₅₀ of 1134.5 ppm. Crassicauline A induces arrhythmia at a dose of 0.10 mg/kg .

Cat. No.	Product Name	Chemical Structure

HY-W010950S

Flecainide-d3
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B1470S

Azaperone-d4

Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-B0006CS

(R)-Carvedilol-d4

(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks